<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
    <channel>
        <title><![CDATA[@creativebioarray - blog]]></title>
        <description><![CDATA[]]></description>
        <link>https://youemerge.com/creativebioarray</link>
        <lastBuildDate>Mon, 14 Sep 2026 16:46:20 -0700</lastBuildDate>
        <atom:link href="https://youemerge.com/feed/blog/creativebioarray" rel="self" type="application/rss+xml" />
                    <item>
                <title><![CDATA[Advanced Transporter Screening Solutions for Drug Development - @creativebioarray]]></title>
                <link>https://youemerge.com/creativebioarray/blog/24141/advanced-transporter-screening-solutions-for-drug-development</link>
                <guid>https://youemerge.com/creativebioarray/blog/24141</guid>
                <description><![CDATA[Transporters represent a crucial family of membrane proteins in the human body, comprising solute carrier transporter and ATP-binding cassette transporter families. They play essential roles in absorbing, distributing, and excreting various molecules, both exogenous and endogenous. Given their significance in drug metabolism and the therapeutic landscape, understanding transporters is vital for successful drug development.<br>
Importance of Transporter Screening<br><br>
Transporters are expressed across various human tissues and are integral to drug pharmacokinetics. Their potential therapeutic targets are being explored for a range of conditions, including diabetes, hypertension, major depression, and constipation. However, much remains unknown about the endogenous substrates and physiological functions of many transporters. Understanding the interactions between therapeutic compounds and transporters early in drug development is critical for selecting candidates with favorable drug metabolism and safety profiles.<br>
Creative Bioarray’s Transporter Screening Services<br><br>
At Creative Bioarray, we offer specialized transporter panels and customized screening services designed to identify novel compounds targeting transporters. Our screening services are grounded in robust methodologies and include:
<br>
FDA transporter screening panel<br>
Monoamine transporter models<br>
Other advanced cell models tailored for specific research needs.<br>
<br>
Key Features of Our Services<br>
<br>
<br>
High-Quality Assays: We employ robust transporter uptake and inhibition assays to ensure quick and efficient screening of new molecular entities (NMEs). The results provide excellent signal-to-background ratios and Z-scores.<br>
<br>
<br>
Coverage of Endpoints: Our transporter screening services cover a wide range of endpoints, including P-glycoprotein (P-gp) inhibition, Breast Cancer Resistance Protein (BCRP) substrate identification and inhibition, and SLC transporter assessments for major transporters.<br>
<br>
<br>
Preclinical Studies: We extend our expertise to preclinical hepatic Oatp uptake transporter assessments, identifying both substrate and inhibition pathways relevant to species such as rats, dogs, and Cynomolgus monkeys.<br>
<br>
<br>
Versatile Technologies: Our advanced technologies for transporter screening include fluorescence methods, radioactive assays, electrophysiology techniques, atomic absorption spectrophotometry (AAS), and mass spectrometry.<br>
<br>
<br>
Customization and Efficiency<br><br>
Understanding that every research project is unique, we offer customization of our screening projects. This flexibility allows for tailored solutions to specific research objectives and timelines, featuring short turnaround times for results.]]></description>
                <pubDate>Mon, 07 Sep 2026 19:11:37 -0700</pubDate>
            </item>
            </channel>
</rss>